Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Japan Tissue Engineering Co., Ltd. ( (JP:7774) ) is now available.
Japan Tissue Engineering Co., Ltd. has received approval for the expanded use of its autologous cultured cartilage product, JACC, for treating osteoarthritis. This approval marks a significant advancement in addressing the challenges of cartilage regeneration, offering a new treatment option for patients who do not respond to conventional therapies. J-TEC plans to make JACC available to eligible patients soon and aims for insurance coverage by December 2025, potentially impacting the treatment landscape for osteoarthritis in Japan.
More about Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. (J-TEC) is a pioneer in regenerative medicine in Japan, focusing on developing innovative solutions to address unmet medical needs worldwide. The company specializes in creating autologous cultured tissues, such as their product JACC, which is used for cartilage repair.
Average Trading Volume: 284,887
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen25.46B
For detailed information about 7774 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue